Substance Related Disorders Clinical Trial
— F_DDSIOfficial title:
French Validation of the Dual Diagnosis Screening Interview (F_DDSI)
In France, there are no tools for screening psychiatric comorbidities for individuals with Substance Use Disorders. The literature shows that the cooccurrence of these psychiatric disorders in the same individual is frequent. It negatively impacts the healing prognosis, complicates the diagnostic processes and the type of care to be introduced for patients. The creation of reliable, fast and easy-to-use tools for caregivers and researchers is therefore necessary to improve quantitatively and qualitatively the care of patients. There is a Spanish scale that meets these criteria, the Dual Diagnostic Screening Interview (S_DDSI). The main objective of this study is to validate the DDSI in French. The secondary objectives are the evaluation of the psychometric qualities of F_DDSI (French version) and adaptation of this scale into an application for Android and iOS.
Status | Recruiting |
Enrollment | 210 |
Est. completion date | June 30, 2019 |
Est. primary completion date | January 31, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: Phase 2 : Patients coming for consultation in the department or day hospital Phase 3: Subjects presenting for one or more substances a diagnosis of Substance Use Disorders (SUD) according to the DSMV criteria. Exclusion Criteria: Phase 2 - Subject who do not understand French - Subject unable to answer questions cognitively Phase 3 - Subject who do not understand French - Subject unable to answer questions cognitively - Subjects with a mental disorder of the axis I of the DSMIV not stabilized making impossible the filling of the questionnaire (in particular acute states delusional and dissociative) - Subjects who participated in the pre-test phase (2) |
Country | Name | City | State |
---|---|---|---|
France | CHU de Clermont-Ferrand | Clermont-Ferrand | Auvergne |
France | CH Etienne Clémentel | Enval | Auvergne |
Lead Sponsor | Collaborator |
---|---|
University Hospital, Clermont-Ferrand |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The response rates for each of the item composing the instrument | From March 14, 2017 to June 2019 | ||
Primary | Psychometric qualities of the new scale | Sensitivity, specificity, and the positive and negative predictive values for each disorder measured by the DDSI will be calculated in comparison with the MINI | From March 14, 2017 to June 2019 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT01655615 -
Does Delaying Adolescent Substance Use Lead to Improved Cognitive Function and Reduce Risk for Addiction?
|
N/A | |
Completed |
NCT01430741 -
MISSION-Vet HUD-VASH Implementation Study
|
N/A | |
Active, not recruiting |
NCT02408952 -
Screening for Youth Alcohol and Drug Use: A Study of Primary Care Providers
|
N/A | |
Completed |
NCT02520271 -
Ostrobothnia Depression Study (ODS). A Naturalistic Follow-up Study on Depression and Related Substance Use Disorders
|
N/A | |
Completed |
NCT01976702 -
Multi-Level HIV Prevention for Pregnant Drug Abusers
|
N/A | |
Active, not recruiting |
NCT05397925 -
Effectiveness of a Training Program for Self-management of the Substance Addiction Consequences - a Study Protocol
|
N/A | |
Completed |
NCT01709552 -
Brief Intervention for Substance Use and Partner Abuse Among Females in the ER
|
N/A | |
Completed |
NCT03868930 -
Multisite RCT of STEP-Home: A Transdiagnostic Skill-based Community Reintegration Workshop
|
N/A | |
Completed |
NCT01936857 -
Buprenorphine to Improve HIV Care Engagement and Outcomes
|
Phase 4 | |
Completed |
NCT02492893 -
Yoga Intervention for Substance Use and ART Adherence in Community Reentry
|
N/A | |
Completed |
NCT00227877 -
Screening and Brief Advice to Reduce Teen Substance Use
|
N/A | |
Completed |
NCT01366716 -
Contingency Management for Cocaine Dependence: Cash Versus Vouchers
|
N/A |